The biopharmaceutical company said before the market opened that the trial evaluated bosakitug’s efficacy and safety in patients with the condition. The investigational therapy is being studied for various inflammatory conditions.
“We are disappointed that the Admiration trial did not overcome the historical challenges of addressing atopic dermatitis with an anti-thymic stromal lymphopoietin monoclonal antibody alone,” Chief Executive Officer Neal Walker said. He added that the results “do not change our development priorities.”

Comments (0)
No comments yet. Be the first!